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Effects of Endothelin-1 on Hepatic Blood Flow
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ARTHUR REVHAUG
Departments of Surgery and Anaesthesiology2, University Hospital ofTromos, Norway
Endothelin-1 belongs to a family of potent vasoconstrictors, recently isolated from endothelial cells.
Endothelin-1 has a variety of hepatic effects and hepatic clearance from the circulation is important.
Elevated plasma concentrations of Endothelin-1 are found after orthotopic liver transplantation and in
cirrhosis with ascites.
This study in piglets on hepatic bloodflowwas designed to compare differences in effects between central
venous and intraportal injection of endothelin-1, and to evaluate effects of repeated injections. Central
venous injection of endothelin-1 caused a larger reduction in portal vein flow, while intraportal injection
caused a larger increase in portal vein pressure. Repeated injections resulted in a reduction in portal vein
flow and an increase in portal vein vascular resistance.
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Endothelin-1 was isolated from cultured porcine aor-
tic endothelial cells in 19881. The hemodynamic re-
sponses to endothelin are complex with a marked
heterogeneity among species and different vascular
beds. It is a potent vasoconstrictor in most vascular
beds2-5, but vasodilatory effects, interaction with
endothelium-derived relaxing factors, dosage de-
pendency, and regional differences have also been
described6-1. In pigs, endothelin is released during
endotoxin shock and asphyxia11. In patients, plasma
levels of endothelin-1 are associated with the severity
of sepsis2, increased plasma levels are found after
orthotopic liver transplantation3, and in cirrhosis
with ascites
14 have also been reported. In the liver,
endothelin-1 diminishes microcirculation15, and ex-
hibits non-vascular effects like stimulated synthesis of
mediators in Kupffer cells
16 and increased glucose
production7.
Endothelin-1 remains stable for up to one hour in
blood, suggesting little enzymatic or spontaneous
degradation. The rapid decrease of endothelin-1 lev-
els from the circulation is mainly due to removal by
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parenchymal tissue2’8. Liver and lung have an impor-
tant clearing function in several species, including
man, while clearance in the porcine lung has been
reported to be negligible 19.
The vasoconstrictor effects of endothelin-1 are
more pronounced with extraluminal than
intraluminal application, indicating a paracrine func-
tion2. The high fractional uptake and rapid clearance
of endothelin-1 in several vascular beds further indi-
cate that the site of origin is of importance. The liver
contributes in maintenance of hemodynamic
homeostasis by handling a multitude of vasoactive
substances released into the portal blood stream in
health and disease. Release of endothelin-1 into the
portal vascular bed with first pass through the liver
may have other effects on hepatic blood flow than a
systemic release.
This study was designed to compare the effects of
endothelin-1 on hepatic blood flow after central ve-
nous and intraportal injection, and to evaluate the
effects of repeated injections. Changes in portal vein
flow induces inverse changes in hepatic arteryflow. An
attempt to distinguish these effect from systemic
effects was made by concomitant recording of several
other hemodynamic variables.
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MATERIALS AND METHODS
The protocol was approved by the local Committee
for Animal Experiments. Six Norwegian Landrace
piglets weighing between 24 and 27 kg served as their
own controls. The animals received a bolus injection
of 10 nmol endothelin- (Novabiochem, L/iufelfingen,
Switzerland) centralvenously and intraportally. Flow
in the portal vein, in the hepatic artery, and in the right
renal artery, and pressure in the portal vein, in the
superior caval vein, in the aorta, and in the pulmonary
artery, were recorded continuously. The injections
were separated by an interval of 30 minutes and the
order of the injections was randomised. The injection
time was 30 seconds. Three baseline periods were
defined. The last five minutes before each injection
were defined as Baseline 1 and Baseline 2, while Base-
line 3 was defined from 30 to 35 minutes after the last
injection. Basline values were used to evaluate the
preinjection conditions and the effects of repeated
injections. Peak and mean (for a single injection) de-
viation from the preceding baseline were used to
compare effects of intraportal and centralvenous in-
jections. When biphasic, peak effect was the amplitude
with the larger absolute value. Mean effect was calcu-
lated from the area under the curve for 10 minutes
after each injection. Integrals below zero level were
defined as negative.
Surgical Procedure and Measurements
The piglets were sedated in the Animal Department
with ketamine (Ketalar(R), Parke-Davis, S.A., Barce-
lona, Spain) 750 mg i.m. and mg atropinsulphate
(Atropin(R), Hydropharma, Oslo, Norway). In the
laboratory anaesthesia was induced with 5%
isoflurane (Forene(R), Abbott Laboratories Ltd,
Queensborough, UK), 15 mg midazolam
(Dormicum(R), Roche, Basel, Switzerland), and 0.5 mg
fentanyl (Leptanal(R), Janssen Pharmaceutica, Beerse,
Belgium). After endotracheal intubation, isoflurane
was discontinued. The animals were ventilated (Servo
Ventilator 900, Elema-Sch6nander, Stockholm,
Sweden) With O2/N20,6.51/min during surgery, and
discontinuation of N20 at least 30 min before he
experiments. FiO2 was 0.5. A uniform level of anaes-
thesis was maintained with a continuous infusion of
ketamine (10 mg/kg/h during surgery, 5 mg/kg/h
during the experiments) and midazolam 0.5 mg/kg/h.
Blood temperature was maintained at 38+1C with a
heating pad.
Pulmonary artery pressure and central venous pres-
sure were monitored bymeans ofa 5 F Edwards Swan-
Ganz catheter (Baxter Healthcare Corp., Santa Ana,
CA, USA) inserted through the rightjugular vein. A 7
F Edwards Swan-Ganz catheter was inserted into the
aorta via the left carotid artery to monitor aortic
pressure. The 5 F Swan-Ganz catheter was used to
measure cardiac output. The animals were given
heparin 200 IU/kg and a continuous infusion ofRing-
ers acetate at a rate of 20 ml/kg/h. The bladder was
drained via a cystotomy. Following a midline incision,
limited dissection was performed to permit placement
of perivascular flow probes around the portal vein
(6 mm), the heptaic artery (3 mm), and the renal artery
(2 mm). Care was taken to preserve the perivascular
nerves. A central venous catheter (Secalon T, Viggo-
Spectramed, Swindon, UK) was inserted into the
portal vein.
Pressures were measured continuously with cali-
brated pressure transducers (Transpac 3, Abbott
Critical Care Systems, North Chicago, III., USA).
Flow was measured continuously with a ultrasonic
transit-time flowmeter (Transonic Animal Research
Flowmeters T208, Transonic Systems Inc. Ithaca,
NY, USA). Pulsatile pressures and flows were moni-
tored while mean flow signals (0.1 Hz second order
Butterworth low-pass filtered) and mean pressure sig-
nals (0.05 Hz low-pass filtered) were recorded on a
thermal chart recorder (Gould ES 2000, Gould Inc.,
Valley View, OI, USA). Heart rate was obtained from
a digital display on the amplifier based on the pulsatile
aortic pressure. Arterial and central venous pH, Po2,
Pco2, base excess and O saturation were analysed at
the end ofevery baseline period by anABL3 Acid Base
Laboratory (Radiometer, Copenhagen, Denmark). A
standard 3-lead electrocardiogram via subcutaneous
electrodes was displayed on a EKG monitor (Dias-
cope, Simonsen-Wedel, Copenhagen, Denkark) and a
control heart rate obtained from the digital display.
Calculations
Systemic vascular resistance, hepatic artery vascular
resistance and portal vein vascular resistance were
calculated from aortic pressure, central venous pres-
sure, portal vein pressure cardiac output and hepatic
artery flow.
Statistics
Statistics were calculated on a Macintosh Quadra 950
using SuperANOVA (Abacus Concepts, Inc.,ENDOTHELIN-1 AND HEPATIC BLOOD FLOW 155
Berkeley, CA, USA). ANOVA for repeated measures
(multivariate approach, type III sum of squares) was
used to evaluate differences in baseline trends for
hemodynamic variables and blood gas analysis with
time as a main effect. Contrast comparisons ofmeans
were used to evaluate pre injection differences in base-
line values (Baseline 1 and Baseline 2). Paired t-tests
were used to compare peak andmean effects ofcentral
venous and intraportal injection of endothelin-1. Val-
ues are presented as mean + SEM. Significance level p
0.05.
increased portal pressure was not significant (p -. 10),
but the increase in portal vein vascular resistance was
significant (p .03) with a trend towards difference in
pre-injection values (p .07). There was no effect on
hepatic artery flow (p .52), cardiac output (p .35)
and heart rate (p .21). Aortic pressure increased
significantly (p .003), but systemic vascular resist-
ance did not (p = .54). Central venous pressure de-
creased significantly (p .003). Blood gas analysis
revealed a non-significant trend towards decline inpH
(p .13).
RESULTS
All animals were included in the study. Due to techni-
cal difficulties (acoustic error), renal artery flow is
missing in one animal.
Effects ofRepeated Injections ofEndothelin-1 on
Baseline Values
Baseline measurements are presented in table 1. The
decline in portal vein flow was significant (p .001).
The difference between the pre-injection baseline lev-
els were also significant (p .03). The trend towards
Differences between Central Venous and lntraportal
Injections ofEndothelin-1
Peak and mean effects of endothelin-1 after central
venous and intraportal injections are presented in ta-
ble 2. The reduction in portal vein flow was signifi-
cantly larger after central venous injection (p .0005
for peak reduction, p .0006 formean reduction). The
increase in aortic pressure was significantly larger af-
ter central venous injection (p .002 for peak increase,
p .005 for mean increase). Portal vein pressure was
the only response significantly larger after intraportal
injection of endothelin-1 (p .002 for peak increase,
p .0005 for mean increase). The effect on hepatic
Table 1 Baseline hemodynamic measurements
Hemodynamic variables Baseline 1 Baseline2 Baseline3 p
Hepatic artery flow (ml/min)
Portal vein flow (ml/min)
Renal artery flow (ml/min)
Portal pressure (mm Hg)
Central venous pressure (mm Hg)
Pulmonary artery pressure (mm Hg)
115 + 11 102 + 18 101 + 10
586 + 13 535 + 18 478 + 30
86 + 29 94 + 29 92 + 30
4.4 + 0.4 5.5 + 0.6 5.6 + 0.3
3.7 + 0.3 3.4 + 0.2 3.4 + 0.3
14.2 + 1.6 15.8 + 1.0 14.8 + 1.1
Aortic pressure (mm Hg) 65 + 2 74 + 4 76 + 4
Cardiac output (L/min) 2.2 + 0.2 2.5 + 0.2 2.4 + 0.1
Heart rate (per min) 75 + 4 83 + 6 90 + 8
0.52
0.001
0.60
0.11
0.003
0.43
0.003
0.35
0.21
Table 2 Hemodynamic effects of Endothelin-1 after centralvenous and intraportal injection
Hemodynamic variables Peak effect Peak effect p Mean effect
of C. V. inj. of 1. P. inj. of C. V. inj.
Mean effect
ofI.e. inj.
Portal vein flow (mL/min)
Hepatic artery flow (mL/min)
Renal artery flow (mL/min)
Portal vein pressure (mm Hg)
Central venous pressure (mm Hg)
Pulmonary artery pressure (mm Hg)
Aortic pressure (mm Hg)
-431 + 79 -156+ 57 0.0005 -293 +63
14 + 120 -30 + 62 0.45 8 + 32
-8 + 68 10 + 26 0.48 -10 + 31
3.0 + 1.5 6.5 + 2.4 0.002 1.7 + 0.8
5.2 + 5.4 1.2 + 1.8 0.11 1.5 + 2.7
7.3 + 7.1 1.5 + 0.5 0.11 2.8 + 3.8
52 + 18 7 + 9 0.002 18 + 8
-86 + 28
-19 + 38
6+10
4.3 + 1.5
-0.5 + 0.8
-0.5 + 0.5
2+4
0.0006
0.16
0.23
0.OOO5
0.11
0.10
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artery flow was less consistent, showing a mixture of
vasoconstrictor and vasodilator effects. The effect on
flow in the renal artery was similar to the effect on the
hepatic artery.
Fig. shows a thermal chart tracing from an animal
that received the intraportal injection first and fig. 2 is
from an animal that received the central venous injec-
tion first. The differences in effects are easily recog-
nised in both figures.
DISCUSSION
This study demonstrates that the effect of a bolus
injection of endothelin-1 on portal blood flow is sig-
nificantly less when injected into the portal vein com-
pared to the effect of central venous injection Thus,
the larger amount of endothelin-1 that reaches the
liver after an intraportal injection has less impact on
portal vein flow than the smaller amount reaching the
liver after a central venous injection. On the other
hand, we found a larger increase in portal vein pres-
sure after intraportal injection, reflecting the larger
amount being presented to the portal vascular bed,
creating a more massive vasoconstriction here, while
correspondingly less reaches the systemic circulation.
Both findings are in accordance with portal vein flow
being mainly dependant on splanchnic inflow, while
portal venous resistance influence portal pressure
only, having little impact on portal vein flow21. Consist-
ently, the peak reduction in portal vein flow precedes
the peak increase in portal vein pressure (fig.1 and
fig.2).
The differences in pre-injection baseline levels for
portal vein flow and pressure have the same direction
as the investigated differences between the two injec-
tion modes. Thus they tend to obscure rather than
enhance any real differences.
The effect of endothelin-1 on hepatic artery flow
is complex. In addition to the direct effects of endo-
thelin-1, the enhanced reduction in portal vein flow
induces a considerable vasodilator effect due to the
22 hepatic artery buffer response When the central ve-
nous injection was given before the intraportal injec-
tion (fig.2), the effect was a marked reduction in
hepatic arteryflow. However, when the central venous
injection of endothelin-1 was given after the
intraportal injection, the effect was a marked increase
in hepatic artery flow (fig. 1). We are unable to explain
the presence ofa "hepatic artery buffer response"- like
effect only when the central venous injection was the
second event, but occupation ofreceptors may change
the balance between vasoconstriction (endothelin-1)
and vasodilatation (hepatic artery buffer response).
However, the same phenomenon is observed for the
renal artery flow, indicating the occurrence of a differ-
ent systemic effect rather than a local hepatic artery
response. Little or no "hepatic artery buffer"-like re-
sponses were seen in connection with the smaller por-
tal vein flow reductions after intraportal injections.
It is of hemodynamic importance not only how
fast endothelin-1 is cleared, but also in which organ
it is trapped. Wagner et al. showed pulmonary clear-
ance to be a main cause of the short half-life of
endothelin-1 in man, though splanchnic and pulmo-
nary fractional extraction rates were comparable 19.
Increased pulmonary artery pressure was not a con-
stant finding in our study, indicating a minor binding
capacity in the porcine lung. A short half-life (77s) for
endothelin-1 is reported in the pig23. The observed
hemodynamic effects are clearly more long-lasting,
reflecting the ability of endothelin-1 to bind tightly to
its receptors.
There was a significant increase in baseline portal
vein vascular resistance, and the significant downslide
in baseline portal vein flow combined with unchanged
cardiac output represents a redistribution at the ex-
pense of the gut. Since elevated plasma levels of
endothelin-1 are found in ascites and sepsis, these
effects may be of pathophysiological importance.
CONCLUSION
Central venous injection of endothelin-1 causes a
larger decrease in portal vein flow and a smaller in-
crease in portal vein pressure than intraportal injec-
tion. The combined effect of repeated injections of
endothelin-1 is a lasting reduction in portal vein flow
and an increase in portal vein vascular resistance.
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